Oncology - break-points, probes, therapies Flashcards Preview

Oncology > Oncology - break-points, probes, therapies > Flashcards

Flashcards in Oncology - break-points, probes, therapies Deck (15)
Loading flashcards...
1
Q

inv(3) or t(3;3)

A

AML

inv(3)(q21.3q26.2)

t(3;3)(q21.3;q26)

GATA2;MECOM

ELN adverse

2
Q

t(8;21)

A

AML

t(8;21)(q22;q22.1)

RUNX1-RUNX1T1

ELN favourable

3
Q

inv(16)

A

AML

inv(16)(p13.1q22)

CBFB-MYH11

ELN favourable

4
Q

t(9;11)

A

AML

t(9;11)(p21.3;q23.3)

MLLT3-KMT2A

ELN Intermediate

5
Q

t(6;9)

A

AML

t(6;9)(p23;q34.1)

DEK-NUP214

ELN Adverse

6
Q

t(15;17)

A

APL

t(15;17)(q24;q21)

PML-RARA

Favourable if treated with ATRA

7
Q

NPM1 mutation

A

Favourable

8
Q

FLT3-ITD

A

Poor

9
Q

NPM1 mutation with no/low FLT-ITD

A

Favourable

10
Q

NPM1 mutation and FLT3-ITD high

A

Intermediate

FLT3 inhibitors = midostaurin

11
Q

Wild type NPM1 with no/low FLT3-ITD

A

Intermediate

12
Q

Wild type NPML with high FLT3-ITD

A

Adverse

FLT3 inhibitors = midostaurin

13
Q

-5 or del(5q), -7, -17/abn(17p)

A

Adverse

14
Q

Mutated RUNX1 or ASXL1 or TP53

A

Adverse

15
Q

Novel therapies for AML

A

FLT3 inhibitors

Epigenetic therapies that target the metabolic enzymes IDH1 and IDH2 that are frequently mutated in AML

Targeted immunotherapy CD33, CD123,
CLEC12A (AML antigenic targets)

Engineered chimeric antigen receptor T (CAR-T) cells target CD33 and CD123 are in early trials